References
- 1. Daptomycin. (2006). In Klasco RK (Eds.), Drugdex system, vol. 129. Greenwood Village (CO): Thomson Micromedex
- 2. Fowler, V.G., Boucher, H.W. & Corey, G.R. (2006). Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med, 355(7), 653-66510.1056/NEJMoa05378316914701
- 3. Davis, S.L., McKinnon, P.S. & Hall, L.M. (2007). Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Pharmacotherapy, 27(12), 1611-161810.1592/phco.27.12.161118041881
- 4. DIALOGO SUI FARMACI n. 4/2007 (profilo aggiornato al 26 settembre 2007)
- 5. Daptomicina. European Public Assessment Report (EPAR) - EMEA www.emea.europa.eu/humandocs/PDFs/EPAR/cubicin/2907006en6.pdf (accesso del 18.05.2007)
- 6. Fey, P.D. et al. (2003). Comparative molecular analysis of community-or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother, 47, 196-20310.1128/AAC.47.1.196-203.200314902712499191
- 7. Steenbergen, J.N., Alder, J., Thorne, G.M. & Tally, F.P. (2005). Daptomycin: a lipopeptide antibiotic for the treatment of serious Grampositive infection. Antimicrob Chemother, 55(3), 283-28810.1093/jac/dkh54615705644
- 8. Clinical Laboratory Standards Institute. (2010). Performance standards for antimicrobial susceptibility testing. Twentieth Informational Supplement. CLSI; p. M100-S20
- 9. EUCAST Clinical Breakpoint Table v. 4.0, valid from 2014-01-01
- 10. http://www.antibiotics-info.org